Product Description
Sulbactam is in a class of medications called beta-lactamase inhibitors. It works by preventing bacteria from destroying ampicillin. (Sourced from: https://medlineplus.gov/druginfo/meds/a693021.html)
Mechanisms of Action: LACTB Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Brazil | Bulgaria | Chile | China | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | Estonia | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Korea | Lithuania | Malaysia | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Spain | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States, Unknown Location
Active Clinical Trial Count: 8
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Respiratory Tract Infections|Urinary Tract Infections
Phase 2: Bronchiectasis|Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease|Pneumonia|Pyelonephritis
Phase 1: Acinetobacter Infections|Arthritis, Infectious|Bacteriuria|Cellulitis|Communicable Diseases|Cystitis|Erysipelas|Gonorrhea|Healthy Volunteers|Lung Abscess|Meningitis, Bacterial|Osteoarthritis|Osteomyelitis|Pelvic Infection|Peritonitis|Pharyngitis|Pneumonia, Bacterial|Sepsis|Sinusitis|Soft Tissue Infections|Tonsillitis|Wound Infection
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06801223 |
CS2514-2023-002 | P1 |
Recruiting |
Communicable Diseases|Acinetobacter Infections |
2028-05-05 |
12% |
2025-04-02 |
Primary Endpoints|Start Date |
CTR20221980 |
CTR20221980 | P1 |
Completed |
Healthy Volunteers |
2023-05-22 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20130509 |
CTR20130509 | P1 |
Recruiting |
Lung Abscess|Pharyngitis|Cystitis|Pelvic Infection|Pneumonia, Bacterial|Tonsillitis|Gonorrhea|Sinusitis|Erysipelas|Bacteriuria|Arthritis, Infectious|Osteomyelitis|Peritonitis|Wound Infection|Cellulitis|Bronchitis, Chronic|Urinary Tract Infections|Respiratory Tract Infections|Pyelonephritis|Osteoarthritis|Soft Tissue Infections|Bronchiectasis|Meningitis, Bacterial|Sepsis |
None |
2025-04-29 |
Patient Enrollment |
|
CTR20131026 |
CTR20131026 | P2 |
Recruiting |
Unknown |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20130998 |
CTR20130998 | P2 |
Recruiting |
Urinary Tract Infections|Respiratory Tract Infections |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20132859 |
CTR20132859 | P2 |
Recruiting |
Chronic Obstructive Pulmonary Disease|Bronchitis, Chronic|Urinary Tract Infections|Pyelonephritis|Pneumonia|Respiratory Tract Infections|Bronchiectasis |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
2020-001397-30 |
2020-001397-30 | P3 |
Active, not recruiting |
Unknown |
2024-09-03 |
2022-03-13 |
Treatments |
|
CTR20132537 |
CTR20132537 | P3 |
Recruiting |
Urinary Tract Infections|Respiratory Tract Infections |
None |
2025-04-29 |
Patient Enrollment|Treatments |